QualityMetric and Pulse Infoframe announced today their partnership and vision to create the first scientifically validated rare disease instruments across conditions. Once deployed, these instruments will benefit not only rare disease patients and families, but also researchers and drug developers working to help this vastly underserviced population as they advance rare disease care and treatments.

Ms. Host’s distinguished career spans 20+ years, with progressively larger leadership roles in healthcare across life sciences, provider, and payer markets.

Mr. Hart will join the team led by Chief Executive Officer Garth “Gus” Gardner, who has been in that role since soon after the VSCP-led recapitalization of the company in August of 2020.

QualityMetric’s own Kimberly Raymond, Andrew Lovley, and Michelle White co-author a new study on the humanistic burden of hereditary transthyretin (hATTR) amyloidosis from the patient’s perspective.

QualityMetric’s Vice President and Senior Scientist, Mark Kosinski, co-authors a study for determining whether the content of the Asthma Control Test (ACT) serves as a valid measure of asthma control.

Our experts provide medical device clients with leading strategic measurement services, qualitative and quantitative research and patient journey studies, PRO outcomes analyses, rare disease research, and PRO regulatory support services.

As pharma, biotech, medical device companies and academic researchers race to discover treatments for COVID-19, they require measurement and outcomes reporting for capturing real-world evidence.

We want to inform you of a recent development that will allow us to enhance the services and support we provide.

Gardner’s appointment comes as the company seeks to build on its position as the preeminent provider of Patient Reported Outcomes (PRO) and Clinical Outcome Assessments (COA) solutions and services to healthcare and life sciences companies.